Infectious Disease Treatment Market in China 2016-2020

Infectious Disease Treatment Market in China 2016-2020

  • May 2016 •
  • 125 pages •
  • Report ID: 3884145 •
  • Format: PDF
About the Infectious Disease Treatment Market in China

Infectious diseases are caused by pathogenic microorganisms such as bacteria, parasites, fungi, or viruses. They can be transmitted from one person to another through direct or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on target organism, anti-infective drugs can be categorized into antibacterial, antifungal, antiviral, and antiparasitic.

Technavio’s analysts forecast the infectious disease treatment market in China to grow at a CAGR of 5.01% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the infectious disease treatment market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat infectious diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

Technavio's report, Infectious Disease Treatment Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.

Key vendors
- F. Hoffmann-La Roche
- Gilead Sciences
- GSK
- Johnson & Johnson
- Merck
- Pfizer


Other prominent vendors
- Achaogen
- Actelion
- Adenovir Pharma
- AstraZeneca
- Bayer
- Biocryst
- Celsus therapeutics
- Cempra
- Eleven Biotherapeutics
- Exoxemis
- Ferrer International
- Griffin Discoveries
- Hexima
- InSite Vision
- Insmed Incorporated
- KaloBios Pharmaceuticals
- Lytix Biopharma
- Meiji Seika Pharma
- Melinta Therapeutics
- Moberg Pharma
- NanoViricides
- Nektar
- NicOx
- NovaBay
- NovaBiotics
- Ocular Therapeutix
- Panoptes Pharma
- Paratek Pharmaceuticals
- Polichem
- PTC Therapeutics
- RedHill
- Shire
- Starpharma Holdings
- Sun Pharma
- Symbiomix
- Tetraphase Pharmaceuticals
- The Medicines Company
- Theravance Biopharma
- Topica Pharmaceuticals
- Vertex Pharmaceuticals
- Viamet Pharmaceuticals

Market driver
- Use of combination therapies
- For a full, detailed list, view our report

Market challenge
- Development of drug resistant strains
- For a full, detailed list, view our report

Market trend
- Emergence of interferon (IFN)-free therapies
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.